Personalized therapeutics of α₁-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.

about

Efficacy of α-blocker in improving ureteral stent-related symptoms: a meta-analysis of both direct and indirect comparison.

P2860

Q36053787-C720F7C9-151F-4951-9131-05CF182E30AE

P2860

Personalized therapeutics of α₁-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.

Item

http://www.wikidata.org/entity/Q42653540

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Personalized therapeutics of α ...... benign prostatic hyperplasia.

@en

Personalized therapeutics of α ...... benign prostatic hyperplasia.

@nl

type

Item

label

Personalized therapeutics of α ...... benign prostatic hyperplasia.

@en

Personalized therapeutics of α ...... benign prostatic hyperplasia.

@nl

prefLabel

Personalized therapeutics of α ...... benign prostatic hyperplasia.

@en

Personalized therapeutics of α ...... benign prostatic hyperplasia.

@nl

P1476

Personalized therapeutics of α ...... benign prostatic hyperplasia.

@en

P2093

Ling-ling Zhu

http://www.w3.org/2001/XMLSchema#string

Quan Zhou

http://www.w3.org/2001/XMLSchema#string

Zhi-jun Feng

http://www.w3.org/2001/XMLSchema#string

P2860

A Comparison of Varying alpha-Blockers and Other Pharmacotherapy Options for Lower Urinary Tract Symptoms.

alpha(1)-blockers for BPH: are there differences?

alpha1-adrenergic receptors in the lower urinary tract and vascular bed: potential role for the alpha1d subtype in filling symptoms and effects of ageing on vascular expression.

AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations.

Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia.

Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia

EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.

Alfuzosin: a clinically uroselective alpha1-blocker.

Multicenter, prospective, comparative cohort study evaluating the efficacy and safety of alfuzosin 10 mg with regard to blood pressure in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia with or without antihypertensi

α1-Adrenoceptors and muscarinic receptors in voiding function - binding characteristics of therapeutic agents in relation to the pharmacokinetics.

P304

621-622

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CIA.S82435

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25848238

http://www.w3.org/2001/XMLSchema#string

P932

4381895

http://www.w3.org/2001/XMLSchema#string

Personalized therapeutics of α₁-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.

about

P2860

P2860

Personalized therapeutics of α₁-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P932